UK-listed investment fund Imperial Innovations joins GlaxoSmithKline's SR One, fund manager Invesco Perpetual and Lundbeckfond Ventures, backing the d cancer treatment company.
University-backed and UK-listed investment fund Imperial Innovations has helped PsiOxus Therapeutics, a UK-based cancer treatment company, raise £22m ($34m) in a series B round today. It was joined in the round by UK-based pharmaceuticals company GlaxoSmithKline’s corporate venturing unit SR One, fund manager Invesco Perpetual and Lundbeckfond Ventures, which is owned by Denmark-based science research…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
